Metrics
145,251 Downloads
Contact Share
heiDATA is an institutional repository for Open Research Data from Heidelberg University. It is managed by the Competence Centre for Research Data, a joint institution of the University Library and the Computing Centre. If you are interested in publishing your data here, please have a look at our user guide and get in touch with us. Detailed information on heiDATA can be found in our service description.
Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Advanced Search

1 to 10 of 6,080 Results
Vardarli_Supplemental Figure legends.docx
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
MS Word - 13.8 KB - MD5: ba86a43da420eaea333e3062bed27e31
Supplemental Figure legends
Vardarli_Supplemental Table legends.docx
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
MS Word - 13.3 KB - MD5: 7c350502f033008bfdfc0f43b17b6199
Supplemental Table legends
Vardarli_Suppl Fig 10.pdf
Vardarli_Suppl Fig 10.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 123.9 KB - MD5: c2336ab9d2a1150d9356954216d18806
Suppl. Fig. 10. Forest plot for subgroups of ICI types trials investigating hypophysitis/hypopituitarism any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 11.pdf
Vardarli_Suppl Fig 11.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 81.0 KB - MD5: 6b06e3d9ad6b0454073d242b7d5e02f5
Suppl. Fig. 11. Forest plot for cumulative meta-analysis for trials investigating hypophysitis/hypopituitarism any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 12.pdf
Vardarli_Suppl Fig 12.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 123.8 KB - MD5: ee9296c71046c73cc5fe678fec8a7720
Suppl. Fig. 12. Forest plot for subgroups of ICI types trials investigating hypophysitis/hypopituitarism grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 13.pdf
Vardarli_Suppl Fig 13.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 124.0 KB - MD5: aa6c4221952b4830ebf248f5169fc5ef
Suppl. Fig. 13. Forest plot for subgroups of ICI types trials investigating adrenal insufficiency any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 14.pdf
Vardarli_Suppl Fig 14.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 80.9 KB - MD5: 62d291378b75e8e2a2f5a787bcfce5a4
Suppl. Fig. 14. Forest plot for cumulative meta-analysis for trials investigating adrenal insufficiency any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 15.pdf
Vardarli_Suppl Fig 15.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 123.7 KB - MD5: e92bdfe54f4b36c5ebfe57df75bd5ca9
Suppl. Fig. 15. Forest plot for subgroups of ICI types trials investigating adrenal insufficiency grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 16.pdf
Vardarli_Suppl Fig 16.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 80.0 KB - MD5: 7f9fed59c4ed1df3ea37f159e262e680
Suppl. Fig. 16. Forest plot for leave-one out meta-analysis for trials investigating insufficiency grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 17.pdf
Vardarli_Suppl Fig 17.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 80.7 KB - MD5: 0d02b91d5d4afe3e1e0b55c74b735a25
Suppl. Fig. 17. Forest plot for cumulative meta-analysis for trials investigating adrenal insufficiency grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Add Data

Sign up or log in to create a dataverse or add a dataset.

Sign Up Log In
Share Dataverse

Share this dataverse on your favorite social media networks.

Link Dataverse
Reset Modifications

Are you sure you want to reset the selected metadata fields? If you do this, any customizations (hidden, required, optional) you have done will no longer appear.